Former CEO Saurabh Saha was paid $11,877,244 in fiscal year 2025, ↑ up 113.5% from fiscal year 2024 (SEC filing 0001847903-26-000040 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$11,877,244 ↑ Saurabh Saha total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CNTA's next annual pay disclosure, estimated April 29, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Saurabh Saha | $683,884 | $411,000 | $0 | $10,755,360 | $0 | $0 | $27,000 | $11,877,244 |
| Former Chief Executive Officer | ||||||||
| Stephen Kanes | 519,034 | 283,500 | 0 | 5,996,146 | 0 | 0 | 14,000 | 6,812,680 |
| Chief Medical Officer | ||||||||
| John Crowley | 534,625 | 305,235 | 0 | 2,988,975 | 0 | 0 | 14,000 | 3,842,835 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Saurabh Saha | $11,877,244 | $5,563,120 | — | ↑ +6,314,124 |
| Stephen Kanes | 6,812,680 | — | — | — |
| John Crowley | 3,842,835 | 4,120,748 | — | ↓ −277,913 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Centessa Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CNTA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CNTA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CNTA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Saurabh Saha | Option | 91,875 | 3.85 | — |
| Saurabh Saha | Option | 712,500 | 16.9 | — |
| Saurabh Saha | RSU | 108,150 | — | 2,704,832 |
| Saurabh Saha | Option | 31,250 | 9.53 | — |
| Saurabh Saha | Option | 312,433 | 8.01 | — |
| Stephen Kanes | Option | 500,000 | 16.9 | — |
| Saurabh Saha | RSU | 105,700 | — | 2,643,557 |
| John Crowley | Option | 197,918 | 16.9 | — |
| John Crowley | Option | 387,500 | 8.8 | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | — | — | — | — | — |
| 2025 | 2025-06-20 | — | — | — | — | — |
| 2024 | 2024-06-25 | — | — | — | — | — |
| 2023 | 2023-06-22 | — | — | — | — | — |
| 2022 | 2022-06-30 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-12 | —a |
| 2025 | 2025-06-20 | —b |
| 2024 | 2024-06-25 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Saurabh Saha MDIndependent | $683,884 | — | — | — | — | $1,108,884 |
| Carol Stuckley, M.B.AIndependent · Audit (Chair) | 61,318 | 0 | 353,320 | — | 0 | 414,638 |
| Arjun Goyal, M.D., M.Phil, M.B.AIndependent · Audit · Not standing for re-election | 58,818 | 0 | 353,320 | — | 0 | 412,138 |
| Brett Zbar, M.DIndependent · Compensation | 56,318 | 0 | 353,320 | — | 0 | 409,638 |
| Samarth Kulkarni, Ph.DIndependent · Not standing for re-election | 53,818 | 0 | 353,320 | — | 0 | 407,138 |
| Mary Lynne Hedley, Ph.DIndependent · Audit · Not standing for re-election | 51,318 | 0 | 353,320 | — | 0 | 404,638 |
| Mathias Hukkelhoven, Ph.DIndependent · Nominating and Corporate Governance | 46,318 | 0 | 353,320 | — | 0 | 399,638 |
| Francesco De Rubertis, Ph.DIndependent · Board Chair · Not standing for re-election | 0 | 0 | 0 | — | 0 | 0 |
| Mario Alberto Accardi, Ph.DEmployee director · Not standing for re-election | — | — | — | — | — | 0 |
| Annual cash retainer | $42,500 |
|---|---|
| Annual equity retainer | $900,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,011,792 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $1,011,792 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Centessa Pharmaceuticals | 2025 | Saurabh Saha | $683,884 | $0 | $10,755,360 | $0 | $11,877,244 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Saurabh Saha | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Executive Compensation”. As printed: 11,877,244. Filing ↗machine: r2 · c24 · span 396099–396109 |
| 2 | Section 01, Stephen Kanes | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Executive Compensation”. As printed: 6,812,680. Filing ↗machine: r6 · c24 · span 407807–407816 |
| 3 | Section 01, John Crowley | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Executive Compensation”. As printed: 3,842,835. Filing ↗machine: r4 · c24 · span 401948–401957 |
| 4 | Section 08, Saurabh Saha MD | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 1,108,884. Filing ↗machine: span 699104–699373 |
| 5 | Section 08, Carol Stuckley, M.B.A | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 414,638. Filing ↗machine: span 358480–358722 |
| 6 | Section 08, Arjun Goyal, M.D., M.Phil, M.B.A | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 412,138. Filing ↗machine: span 350629–350761 |
| 7 | Section 08, Brett Zbar, M.D | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 409,638. Filing ↗machine: span 352504–352746 |
| 8 | Section 08, Samarth Kulkarni, Ph.D | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 407,138. Filing ↗machine: span 356489–356731 |
| 9 | Section 08, Mary Lynne Hedley, Ph.D | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 404,638. Filing ↗machine: span 354497–354739 |
| 10 | Section 08, Mathias Hukkelhoven, Ph.D | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 399,638. Filing ↗machine: span 360736–361007 |
| 11 | Section 08, Francesco De Rubertis, Ph.D | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 08, Mario Alberto Accardi, Ph.D | DEF 14A | 2026-04-29 | 0001847903-26-000040 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 06, 2026 vote | Form 8-K | 2026-06-12 | 0001193125-26-269474 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-06-20 | 0001847903-25-000093 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 15 | Section 06, 2024 vote | Form 8-K | 2024-06-25 | 0001847903-24-000095 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 1,011,792 + equity 0 + all other 0 = 1,011,792, summed across the director compensation table rows.machine: formula: Σ = 1,011,792 |
| 18 | Centessa Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001847903-26-000040 | CEO total compensation as printed in Centessa Pharmaceuticals's own proxy. As printed: 11,877,244. Filing ↗machine: r2 · c24 · span 396099–396109 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.